Overview

First-in-Human Study of PF-04958242 in Healthy Volunteers

Status:
Completed
Trial end date:
2010-10-16
Target enrollment:
Participant gender:
Summary
The primary objective of this study will evaluate the safety and tolerability of single, escalating doses of PF-04958242 administered orally to healthy adult participants. This study will also evaluate the plasma pharmacokinetics (PK) of single doses of PF-04958242 after single escalating doses of PF-04958242 administered orally to healthy adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Pfizer